Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis
Standard
Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis. / Schiele, Miriam A; Reif, Andreas; Lin, Jiaxi; Alpers, Georg W; Andersson, Evelyn; Andersson, Gerhard; Arolt, Volker; Bergström, Jan; Carlbring, Per; Eley, Thalia C; Esquivel, Gabriel; Furmark, Tomas; Gerlach, Alexander L; Hamm, Alfons; Helbig-Lang, Sylvia; Hudson, Jennifer L; Lang, Thomas; Lester, Kathryn J; Lindefors, Nils; Lonsdorf, Tina B; Pauli, Paul; Richter, Jan; Rief, Winfried; Roberts, Susanna; Rück, Christian; Schruers, Koen R J; Thiel, Christiane; Wittchen, Hans-Ulrich; Domschke, Katharina; Weber, Heike; Lueken, Ulrike.
In: EUR NEUROPSYCHOPHARM, Vol. 44, 03.2021, p. 105-120.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis
AU - Schiele, Miriam A
AU - Reif, Andreas
AU - Lin, Jiaxi
AU - Alpers, Georg W
AU - Andersson, Evelyn
AU - Andersson, Gerhard
AU - Arolt, Volker
AU - Bergström, Jan
AU - Carlbring, Per
AU - Eley, Thalia C
AU - Esquivel, Gabriel
AU - Furmark, Tomas
AU - Gerlach, Alexander L
AU - Hamm, Alfons
AU - Helbig-Lang, Sylvia
AU - Hudson, Jennifer L
AU - Lang, Thomas
AU - Lester, Kathryn J
AU - Lindefors, Nils
AU - Lonsdorf, Tina B
AU - Pauli, Paul
AU - Richter, Jan
AU - Rief, Winfried
AU - Roberts, Susanna
AU - Rück, Christian
AU - Schruers, Koen R J
AU - Thiel, Christiane
AU - Wittchen, Hans-Ulrich
AU - Domschke, Katharina
AU - Weber, Heike
AU - Lueken, Ulrike
N1 - Copyright © 2021. Published by Elsevier B.V.
PY - 2021/3
Y1 - 2021/3
N2 - There is a recurring debate on the role of the serotonin transporter gene linked polymorphic region (5-HTTLPR) in the moderation of response to cognitive behavioral therapy (CBT) in anxiety disorders. Results, however, are still inconclusive. We here aim to perform a meta-analysis on the role of 5-HTTLPR in the moderation of CBT outcome in anxiety disorders. We investigated both categorical (symptom reduction of at least 50%) and dimensional outcomes from baseline to post-treatment and follow-up. Original data were obtained from ten independent samples (including three unpublished samples) with a total of 2,195 patients with primary anxiety disorder. No significant effects of 5-HTTLPR genotype on categorical or dimensional outcomes at post and follow-up were detected. We conclude that current evidence does not support the hypothesis of 5-HTTLPR as a moderator of treatment outcome for CBT in anxiety disorders. Future research should address whether other factors such as long-term changes or epigenetic processes may explain further variance in these complex gene-environment interactions and molecular-genetic pathways that may confer behavioral change following psychotherapy.
AB - There is a recurring debate on the role of the serotonin transporter gene linked polymorphic region (5-HTTLPR) in the moderation of response to cognitive behavioral therapy (CBT) in anxiety disorders. Results, however, are still inconclusive. We here aim to perform a meta-analysis on the role of 5-HTTLPR in the moderation of CBT outcome in anxiety disorders. We investigated both categorical (symptom reduction of at least 50%) and dimensional outcomes from baseline to post-treatment and follow-up. Original data were obtained from ten independent samples (including three unpublished samples) with a total of 2,195 patients with primary anxiety disorder. No significant effects of 5-HTTLPR genotype on categorical or dimensional outcomes at post and follow-up were detected. We conclude that current evidence does not support the hypothesis of 5-HTTLPR as a moderator of treatment outcome for CBT in anxiety disorders. Future research should address whether other factors such as long-term changes or epigenetic processes may explain further variance in these complex gene-environment interactions and molecular-genetic pathways that may confer behavioral change following psychotherapy.
U2 - 10.1016/j.euroneuro.2021.01.004
DO - 10.1016/j.euroneuro.2021.01.004
M3 - SCORING: Journal article
C2 - 33483252
VL - 44
SP - 105
EP - 120
JO - EUR NEUROPSYCHOPHARM
JF - EUR NEUROPSYCHOPHARM
SN - 0924-977X
ER -